Genetic Testing Helps Determine Your Risk for Prostate Cancer скачать в хорошем качестве

Genetic Testing Helps Determine Your Risk for Prostate Cancer

Genetic testing for prostate cancer can help determine your risk, guide treatment decisions, and support earlier screening for high-risk individuals. In this educational webinar hosted by the Prostate Health Education Network (PHEN), experts explain how genetics influence prostate cancer risk and why understanding your genetic profile is an important step in modern cancer care. During the session, Thomas Farrington, founder and president of PHEN, introduces a discussion led by Keith Crawford, Director of Clinical Trials and Patient Education. The presentation breaks down complex genetic concepts, including DNA, gene mutations, and genetic testing, into practical information patients and families can understand. The program also highlights why genetic testing and clinical trial participation are especially important for Black men, who face a significantly higher risk of developing and dying from prostate cancer. Key Topics Covered: • How genetic testing helps determine prostate cancer risk • The difference between germline mutations (inherited) and somatic mutations (acquired) • Why BRCA1 and BRCA2 gene mutations matter in prostate cancer • The role of PARP inhibitors and targeted therapies • How genomic testing can guide personalized prostate cancer treatment • Why Black men face higher prostate cancer risk and mortality • The importance of clinical trial participation and diverse research representation • How genetic information can impact family members and future screening decisions Key Takeaway Prostate cancer is one of the most heritable cancers, and advances in genetic research are changing how the disease is detected and treated. Understanding genetic mutations can help physicians personalize treatment strategies, identify targeted therapies, and recommend screening earlier for those at higher risk. This session also highlights the importance of improving diversity in genetic research and clinical trials, ensuring that future treatments benefit all populations affected by prostate cancer.